Pfizer and Allergan said they are working on a corporate inversion deal that will amount to a reverse takeover under Irish law. The transaction reportedly is valued at $160 billion. The announcement came just days after the IRS previewed regulations that will further reduce the tax benefits of corporate inversions and make such transactions more difficult to achieve. This article discusses both of the issues.